1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. Journal Of Clinical Oncology 1986, 4: 1592-7. PMID: 3534155, DOI: 10.1200/jco.1986.4.11.1592.Peer-Reviewed Original ResearchConceptsAutologous bone marrow supportBone marrow supportInflammatory breast cancerMetastatic breast cancerPartial responseComplete responseBreast cancerPrior chemotherapyMarrow supportTumor regressionHigh-dose combination chemotherapy regimenMetastatic breast cancer patientsHigher partial responsePhase II regimenPrior combination chemotherapyHigh-dose regimenHigh-dose combinationCombination chemotherapy regimenBreast cancer patientsBone marrow harvestEvaluable patientsChemotherapy regimenAgent chemotherapyFirst recurrenceMedian survival
1984
Efficacy of Methylprednisolone in Acute Spinal Cord Injury
Bracken M, Collins W, Freeman D, Shepard M, Wagner F, Silten R, Hellenbrand K, Ransohoff J, Hunt W, Perot P, Grossman R, Green B, Eisenberg H, Rifkinson N, Goodman J, Meagher J, Fischer B, Clifton G, Flamm E, Rawe S. Efficacy of Methylprednisolone in Acute Spinal Cord Injury. JAMA 1984, 251: 45-52. PMID: 6361287, DOI: 10.1001/jama.1984.03340250025015.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryCord injuryEarly case fatalityEfficacy of methylprednisoloneHigh-dose regimenLight touch sensationHigh-dose protocolGroups six weeksNeurological recoveryCase fatalityWound infectionStandard doseMotor functionInitial lesionHigh doseOperative siteSix weeksInjuryMethylprednisoloneTreatment effectsTouch sensationDoseEfficacyMulticenter
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply